CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment

JAMA

Volumn 302, Issue 4, 2009, Pages 385-393

  Mattsson, Niklas ^a,p   Zetterberg, Henrik ^a   Hansson, Oskar ^b   Andreasen, Niels ^c   Parnetti, Lucilla ^d   Jonsson, Michael ^a   Herukka, Sanna Kaisa ^e   Van Der Flier, Wiesje M ^f   Blankenstein, Marinus A ^f   Ewers, Michael ^g,h   Rich, Kenneth ⁱ   Kaiser, Elmar ^j   Verbeek, Marcel ^k   Tsolaki, Magda ^l   Mulugeta, Ezra ^m   Rosén, Erik ^a   Aarsland, Dag ^m   Jelle Visser, Pieter ⁿ   Schröder, Johannes ^j   Marcusson, Jan ^o   De Leon, Mony ⁱ   Hampel, Harald ^g,h   Scheltens, Philip ^f   Pirttilä, Tuula ^e   Wallin, Anders ^a   Eriksdotter Jönhagen, Maria ^c   Minthon, Lennart ^b   Winblad, Bengt ^c   Blennow, Kaj ^a   more..

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF PERUGIA   (Italy)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ADELAIDE AND MEATH HOSPITAL   (Ireland)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^m STAVANGER UNIVERSITY HOSPITAL   (Norway)

ⁿ MAASTRICHT UNIVERSITY   (Netherlands)

^o LINKÖPING UNIVERSITY   (Sweden)

^p SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; THREONINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; PHOSPHOTHREONINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE COURSE; EUROPE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; UNITED STATES; CHEMISTRY; CLINICAL TRIAL; COGNITIVE DEFECT; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHOTHREONINE; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 67651204382     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1064     Document Type: Article

References (46)

1. Blennow K, deLeon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368(9533):387-403.
2. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol. 2004;6(11):1054- 1061.
3. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and earlystage Alzheimer's disease. J Mol Neurosci. 2001;17(2):101-118.
4. Thal LJ. Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(3)(suppl 2):S97-S99.
5. Doody RS, Gavrilova SI, Sano M, et al; Dimebon Investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207-215.
6. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985-1992.
7. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308.
8. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2(10):605-613.
9. Visser PJ, Verhey FR. Mild cognitive impairment as predictor for Alzheimer's disease in clinical practice: effect of age and diagnostic criteria. Psychol Med. 2008;38(1):113-122.
10. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett. 2003;352(1):67-69.
11. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl. 2003;179:47-51.
12. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9(7):705-710.
13. Herukka SK, Hallikainen M, Soininen H, Pirttilä T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64(7):1294-1297.
14. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59(11):1729-1734.
15. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttilä T. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging. 2007;28(4):507-514.
16. Andreasen N, Minthon L, Vanmechelen E, et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett. 1999;273(1):5-8.
17. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228-234.
18. Maruyama M, Matsui T, Tanji H, et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol. 2004;61(5):716-720.
19. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69(7):631-639.
20. Bouwman FH, Schoonenboom SN, van der Flier WM, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging. 2007;28(7):1070-1074.
21. Bossuyt PM, Reitsma JB, Bruns DE, et al; Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ. 2003;326(7379):41-44.
22. Bossuyt PM, Reitsma JB, Bruns DE, et al; Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49(1):7-18.
23. Zetterberg H, Pedersen M, Lind K, et al. Intraindividual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis. 2007;12(3):255-260.
24. Jelle Visser P, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective-cohort study. Lancet Neurol. 2009;8(7):619-627.
25. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26(3):231-245.
26. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285(1):49-52.
27. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673-680.
28. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau(Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336-345.
29. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240-246.
30. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
33. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250-260.
34. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000;59:23-30.
35. McKeith IG, Perry EK, Perry RH; Consortium on Dementia with Lewy Bodies. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Neurology. 1999;53(5):902-905.
36. Brun A, Englund E, Gustafson L, et al; The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57(4):416-418.
37. Consensus report of the working group on "Molecular and Biochemical Markers of Alzheimer's disease." Neurobiol Aging. 1998;19(2):109-116.
38. Kutner MH, Nachtsheim CJ, Neter J, Li W. Applied Linear Statistical Models. 5th ed. New York, NY: McGraw-Hill Irwin; 2004.
39. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329(7458):168-169.
40. Altman DG. Practical Statistics for Medical Research. London, England: Chapman & Hall CRC Press; 1990.
41. Riemenschneider M, Schmolke M, Lautenschlager N, et al. Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett. 2000;284(1-2):85-88.
42. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978;299(17):926-930.
43. Sjögren M, Vanderstichele H, Agren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001;47(10):1776-1781.
44. Panza F, D'Introno A, Colacicco AM, et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. AmJ Geriatr Psychiatry. 2005;13(8):633-644.
45. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.
46. Andersson C, Almkvist O, Engfeldt P, et al. Differential CSF biomarker levels in APOE ε4 positive and negative patients with memory impairment. Dement Geriatric Cogn Disord. 2007;23(2):87-95.